Stereochemistry | ABSOLUTE |
Molecular Formula | C22H22F3N |
Molecular Weight | 357.412 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C2=CC=CC3=CC=CC=C23
InChI
InChIKey=VDHAWDNDOKGFTD-MRXNPFEDSA-N
InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1
Molecular Formula | C22H22F3N |
Molecular Weight | 357.412 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Cinacalcet is a positive allosteric modulator of calcium sensing receptor. The drug is approved by FDA (Sensipar trade name) and used for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis; hypercalcemia in adult patients with parathyroid carcinoma; hypercalcemia in adult patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.
CNS Activity
Originator
Approval Year
Doses
AEs
Overview
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|